本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据《中华人民共和国公司法》《国药集团药业股份有限公 司章程》等相关规定，国药集团药业股份有限公司（以下简称"公 司"或"国药股份"）于 2025 年 9 月 15 日召开职工代表大会， 选举张婷女士（简历见附件）为公司第八届董事会职工董事，任 期自职工代表大会选举通过之日起生效。 特此公告。 国药集团药业股份有限公司董事会 2025 年 9 月 16 日 1 附： 证券代码：600511 证券简称：国药股份 公告编号：临 2025-034 国药集团药业股份有限公司 关于选举职工董事的公告 张婷女士简历：生于 1979 年 10 月，中共党员，硕士研究生 学历，教授级高级政工师。2017 年 5 月至 2018 年 3 月担任中国 医药集团有限公司党群工作副主任、团委书记；2018 年 3 月至 2019 年 1 月担任中国医药集团有限公司党群工作部副主任；2019 年 1 月至 2019 年 11 月担任中国医药集团有限公司公共事务部副 主任（主持日常工作）；2019 年 1 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2025-033 国药集团药业股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 15 日 (二)股东会召开的地点：北京市东城区永定门西滨河路 8 号院 7 楼中海地产广场 西塔 8 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 184 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 469,246,979 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 62.1928 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次会议由董事会召集，董事长刘月涛主持本次会议，会议采用现场投票和网络 投票的方式进行表决，符合《公司法 ...

国枫律股字[2025]A0452 号 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于国药集团药业股份有限公司 2025 年第三次临时股东会的 法律意见书 致：国药集团药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第三次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《国 药集团药业股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的 召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜， 出具本法 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Core Viewpoint - The meeting between Shanxi Provincial Government and China National Pharmaceutical Group aims to enhance cooperation in the pharmaceutical industry, focusing on high-quality development and modernization in Shanxi [1] Group 1: Strategic Cooperation - Both parties discussed the importance of advancing transformation and reform in enterprises, emphasizing the need for a collaborative approach in the pharmaceutical sector [1] - The partnership will leverage strengths to improve the entire pharmaceutical industry chain, including medical institutions, biomedicine, traditional Chinese medicine, and medical equipment production [1] Group 2: Development Goals - The cooperation aims to enhance healthcare service levels and contribute to the construction of a healthy Shanxi [1] - Key areas of focus include medical research innovation, standard enhancement, and the establishment of a comprehensive trade and circulation system for pharmaceuticals [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Core Points - The company, China National Pharmaceutical Group Corporation, is holding its third extraordinary general meeting of shareholders on September 15, 2025, to discuss the election of a new board member [1] - Zhang Ping has been nominated as a candidate for the board of directors, with her professional background detailed in the attached resume [1] - Zhang Ping has no shareholding in the company and does not have any relationships with other directors, senior management, or significant shareholders [2] Summary by Sections Meeting Details - The extraordinary general meeting will take place at 13:30 on September 15, 2025, at a specified location in Beijing [1] - Voting will be available through an internet platform during designated times [1] Election of Directors - The board of directors has proposed the election of Zhang Ping as a candidate for the eighth board of directors [1] - Zhang Ping's professional history includes various roles within China National Pharmaceutical Group, highlighting her experience in marketing management and risk management [1] Candidate Background - Zhang Ping was born in October 1978 and is a member of the Communist Party of China [1] - She has held positions in the company since 2011, with her most recent role being the director of business planning management in the risk and operations management department [1] - She does not hold any shares in the company and has no conflicts of interest with other stakeholders [2]

国药集团药业股份有限公司 1 / 5 SH.600511 国药股份 2025 年第三次临时股东会议程 现场会议时间：2025 年 9 月 15 日 13:30 交易系统平台网络投票时间： 2025 年第三次临时股东会会议资料 股票代码：600511 2025 年 9 月 15 日 2 / 5 SH.600511 一、审议关于选举董事的议案 报告人：罗丽春 总法律顾问、董事会秘书 2025 年 9 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00； 互联网投票平台网络投票时间： 2025 年 9 月 15 日 9:15-15:00 现 场会 议 地点 ： 北 京市 东 城区 永 定门 西 滨河 路 8 号 院 7 楼中海地产广场西塔 8 层会议室 会议议题： 一、审议关于选举董事的议案 3 / 5 SH.600511 关于选举董事的议案 各位股东及股东代表： 公司于 8 月 29 日召开第八届董事会第二十九次会议，审议通过 了《关于提名董事候选人的议案》，提名张平女士（简历见附件）为 公司第八届董事会董事候选人。 以上议案提请股东会审议。 国药集团药业股份有限公司董事会 2025 ...

Core Viewpoint - The announcement details the change of the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation (国药股份) due to the retirement of the previous representative, Liu Xiangsheng, and the appointment of Lu Wenjun as his successor [1][2]. Group 1 - The company received a letter from the underwriting sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for the equity division reform project [1]. - Liu Xiangsheng will no longer continue his duties due to retirement, and Lu Wenjun will take over the responsibilities [1]. - The board expresses gratitude for Liu Xiangsheng's contributions during his tenure [2]. Group 2 - Lu Wenjun has a master's degree and 16 years of experience in investment banking, having participated in various IPOs and financial advisory projects [4].

Core Viewpoint - The announcement details the change in the continuous supervision representative for the equity division reform of China National Pharmaceutical Group Corporation, with the new representative being Mr. Lu Wenjun, who has extensive experience in investment banking [1]. Group 1: Company Announcement - China National Pharmaceutical Group Corporation has received a letter from its sponsor, Shenwan Hongyuan Securities, regarding the change of the continuous supervision representative for its equity division reform [1]. - Mr. Liu Xiangsheng, the previous representative, is retiring and will be succeeded by Mr. Lu Wenjun, who will continue the supervisory duties [1]. - The board expresses gratitude for Mr. Liu's contributions during his tenure [1]. Group 2: New Representative Profile - Mr. Lu Wenjun holds a master's degree and has 16 years of experience in investment banking [1]. - He has led or participated in various IPO projects and private placements, including those for companies such as Furui Special Equipment, Dashengda, and Xianhui Technology [1]. - His experience also includes involvement in bond projects and asset restructuring for several companies, showcasing his extensive background in financial advisory [1].